STOCK TITAN

Shareholder plans $351,617 sale in RYTM (NASDAQ: RYTM) stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A shareholder of RYTM filed a Form 144 notice to sell up to 3,247 shares of common stock through Morgan Stanley Smith Barney LLC on or about February 4, 2026 on NASDAQ. The filing shows an aggregate market value of $351,617.63 for these shares.

The shares to be sold were acquired from the issuer as restricted stock units on February 3, 2025, in the same amount of 3,247 shares. The table also lists 66,736,056 shares outstanding for this class of common stock.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the RYTM Form 144 filing disclose?

The Form 144 discloses that a RYTM shareholder intends to sell up to 3,247 common shares with an aggregate market value of $351,617.63. The planned sale is through Morgan Stanley Smith Barney LLC on NASDAQ around February 4, 2026.

How many RYTM shares are planned for sale and on which exchange?

The filing indicates a planned sale of 3,247 RYTM common shares on the NASDAQ exchange. These shares are to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value reported as $351,617.63 in the notice.

How were the RYTM shares in this Form 144 originally acquired?

The shares were acquired as restricted stock units from the issuer on February 3, 2025. The table shows 3,247 shares acquired on that date, matching the number of shares that the shareholder now plans to sell under this Form 144 notice.

What is the reported market value of the RYTM shares to be sold?

The Form 144 lists an aggregate market value of $351,617.63 for the 3,247 common shares to be sold. This figure reflects the total value used in the notice when describing the planned sale through Morgan Stanley Smith Barney LLC on NASDAQ.

How many RYTM common shares are reported as outstanding in the filing?

The Form 144 table reports 66,736,056 common shares outstanding for RYTM. This number provides context for the planned sale of 3,247 shares but is a baseline figure for the class of stock, separate from the specific transaction disclosed.

When is the approximate sale date for the RYTM shares in this Form 144?

The notice states an approximate sale date of February 4, 2026 for the 3,247 RYTM common shares. The sale is to be executed on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
Rhythm Pharmaceu

NASDAQ:RYTM

RYTM Rankings

RYTM Latest News

RYTM Latest SEC Filings

RYTM Stock Data

7.21B
63.63M
0.65%
105.06%
7.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON